{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:01:35Z","timestamp":1792544495713,"version":"4.5.0"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2820,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1365-2133.2007.08372.x","type":"journal-article","created":{"date-parts":[[2008,2,11]],"date-time":"2008-02-11T09:04:21Z","timestamp":1202720661000},"page":"567-572","source":"Crossref","is-referenced-by-count":101,"title":["An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa"],"prefix":"10.1093","volume":"158","author":[{"given":"E.J.","family":"Giamarellos-Bourboulis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Pelekanou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Antonopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Petropoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Baziaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Karagianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Stavrianeas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Giamarellou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2007,12,12]]},"reference":[{"key":"10.1111\/j.1365-2133.2007.08372.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0007-1226(03)00177-2","article-title":"Hidradenitis suppurativa: pathogenesis and management","volume":"56","author":"Slade","year":"2003","journal-title":"Br J Plast Surg"},{"key":"10.1111\/j.1365-2133.2007.08372.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2133.2006.07556.x","article-title":"Altered innate and adaptive immune responses in patients with hidradenitis suppurativa","volume":"156","author":"Giamarellos-Bourboulis","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2007.08372.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1111\/j.1365-2133.2003.05663.x","article-title":"Infliximab for hidradenitis suppurativa","volume":"149","author":"Sullivan","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2007.08372.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1365-2133.2005.07067.x","article-title":"Etanercept: effective in the management of hidradenitis suppurativa","volume":"154","author":"Cusack","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2007.08372.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1396-0296.2004.04007.x","article-title":"Hidradenitis suppurativa: a review","volume":"17","author":"Wiseman","year":"2004","journal-title":"Dermatol Ther"},{"key":"10.1111\/j.1365-2133.2007.08372.x-BIB6|cit6","first-page":"1547","article-title":"Hidradenitis suppurativa: a treatment challenge","volume":"1554","author":"Shah","year":"2005","journal-title":"Am Fam Physician"},{"key":"10.1111\/j.1365-2133.2007.08372.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","article-title":"Etanercept as monotherapy in patients with psoriasis","volume":"349","author":"Leonardi","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2007.08372.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1046\/j.1365-2133.2003.05390.x","article-title":"Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa","volume":"149","author":"Sartorius","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2007.08372.x-BIB9|cit9","first-page":"1074","article-title":"Long-term infliximab for severe hidradenitis suppurativa","volume":"154","author":"Thielen","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2007.08372.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1517\/14656566.5.8.1767","article-title":"Medical treatment of hidradenitis suppurativa","volume":"5","author":"Jemec","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"10.1111\/j.1365-2133.2007.08372.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-4362.1983.tb02150.x","article-title":"Topical treatment of hidradenitis suppurativa with clindamycin","volume":"22","author":"Clemmensen","year":"1983","journal-title":"Int J Dermatol"},{"key":"10.1111\/j.1365-2133.2007.08372.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0190-9622(98)70272-5","article-title":"Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa","volume":"39","author":"Jemec","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2007.08372.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1365-2133.1986.tb05740.x","article-title":"A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa","volume":"115","author":"Mortimer","year":"1986","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2007.08372.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/archderm.1988.01670070031014","article-title":"Hidradenitis suppurativa. Glucose tolerance, clinical microbiologic, and immunologic features and HLA frequencies in 27 patients","volume":"124","author":"O\u2019Loughlin","year":"1988","journal-title":"Arch Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2133.2007.08372.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2133.2007.08372.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:23:52Z","timestamp":1676384632000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/158\/3\/567\/6643801"}},"subtitle":["Etanercept in hidradenitis suppurativa"],"short-title":[],"issued":{"date-parts":[[2007,12,12]]},"references-count":14,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08372.x","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12,12]]}}}